JPRN-UMIN000014968尚未招募未知
Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapy - Effect of Ipragliflozin on combination with insulin
Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology0 个研究点目标入组 50 人开始时间: 2014年9月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Contraindiction for Ipragliflozin Patients who may have been pregnant or pregnant women Patients who are considered low-nutrition and dehydration
研究者
相似试验
已完成
不适用
Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.Type 2 diabetesJPRN-UMIN000014306akakinen clinic100
已完成
不适用
A study on the efficacy and safety of ipragliflozin monotherapy or combination therapy under clinical use condition: continuous glucose monitoring and self monitoring of urine glucoseType 2 diabetesJPRN-UMIN000014388Kato clinic of Internal medicine30
招募中
不适用
Efficacy and Safety of SGLT2 Inhibitor Ipragliflozin in with Type 1 Diabetes patients using FGMType 1 diabetesJPRN-UMIN000035555Minami Osaka Hospital Internal Medicine20
已完成
不适用
Randomized comparative study of ipragliflozin combination therapy and sitagliptin combination therapy in patients with type 2 diabetes administrating metformiType 2 diabetesJPRN-UMIN000018364iigata University Fuculty of Medicine166
尚未招募
不适用
Efficacy and safety of SGLT2 inhibitor, Ipragliflozin in type 2 diabetes patients.Type 2 diabetes mellitusJPRN-UMIN000013898Chubu-Rosai Hospital Department of Diabetes and Endocrinology15